Jamil Ahmed, MD
Nephrology · Tucson, AZNPI 1588685879
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Bayer at 25.3% of the total. 2025 is the largest year on record at $745, 2.5 times the $295 reported in 2019.
Across 156 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$729
- AstraZeneca$482
- Amgen$272
- Calliditas Therapeutics US Inc.$191
- Vifor Pharma, Inc.$180
- OPKO Pharmaceuticals, LLC$168
- plus $860 from 17 others
Across 20 payments — averaging $2945.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$54K
- CSL Behring$4K
What the payments were for
- Food & beverage$2,74995%
- Education$1335%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 45 | $729 |
| AstraZeneca(2 entities) | 26 | $482 |
| Amgen(2 entities) | 13 | $272 |
| Calliditas Therapeutics US Inc. | 9 | $191 |
| Vifor Pharma, Inc. | 10 | $180 |
| OPKO Pharmaceuticals, LLC | 10 | $168 |
| Boehringer Ingelheim | 6 | $133 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Novartis | 6 | $108 |
| Aurinia Pharma U.S., Inc. | 3 | $68 |
| W. L. Gore & Associates, Inc. | 2 | $64 |
| Akebia Therapeutics Inc | 3 | $56 |
| GSK | 3 | $51 |
| Ardelyx, Inc. | 2 | $37 |
| Travere Therapeutics, Inc. | 3 | $37 |
| Fresenius USA Marketing, Inc. | 2 | $37 |
| Chiesi USA, Inc. | 1 | $33 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Nxstage Medical, Inc. | 1 | $12 |
How this compares
$2,882 in reported general payments places this provider in the 55th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 220 | $172,100 |
| VelphoroSucroferric Oxyhydroxide | 23 | $70,778 |
| JardianceEmpagliflozin | 74 | $53,037 |
| Sevelamer Carbonate | 96 | $28,428 |
| LokelmaSodium Zirconium Cyclosilicate | 29 | $25,679 |
| KerendiaFinerenone | 30 | $25,032 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,028 |
| Prazosin Hcl | 35 | $2,366 |
| Hydralazine Hcl | 195 | $1,931 |
| Potassium Citrate ErPotassium Citrate | 23 | $1,684 |
| Sodium Polystyrene Sulfonate | 22 | $1,573 |
| Amlodipine Besylate | 235 | $1,158 |
| Losartan Potassium | 104 | $1,023 |
| Calcitriol | 79 | $982 |
| Furosemide | 191 | $935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $482 | $197,779249 claims |
| Fresenius USA Marketing, Inc.Velphoro | $37 | $70,77823 claims |
| Boehringer IngelheimJardiance | $133 | $53,03774 claims |
| BayerKerendia | $729 | $25,03230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 259 nephrology providers in Arizona.
Other nephrology in Tucson
- Aneesha ShettyTucson$34K
- David WhittmanTucson$13K
- Bijin ThajudeenTucson$7K
- Mindy JanTucson$7K
- Tausif ZarTucson$6K
- Vincent CampionTucson$5K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.